2 No-Brainer Stocks to Buy Right Now with $1,000

Investors with limited cash can earn two ways and make a fortune with two no-brainer stocks.

| More on:

A small amount of capital is no longer a hindrance to investing in stocks. You don’t need to be flush with cash like the rich to make money in the stock market. With the right investment strategy and choices, $1,000 can go a long way and become a fortune over time.

Healwell AI (TSX:AIDX) and Rogers Sugar (TSX:RSI) are no-brainer stocks to buy right now. Both small-cap stocks are relatively cheap (less than $10 per share combined), but the earning potential is enormous. The healthcare stock is a high-flyer, while the consumer staples stock is a pure-dividend play.

Growth investing

Healwell AI is suitable for growth investors. At only $2.34 per share, the year-to-date gain is an eye-popping 210.7%. A $1,000 investment at year-end 2023 is worth $3,120 today. Market analysts covering AIDX recommend a strong buy rating. Their 12-month average and high price targets are $3.69 and $5, or an upside potential between 57.7% and 113.7%, respectively.

The $370 million healthcare technology company uses artificial intelligence (AI) tools and data science for preventive care and early disease detection. Healwell AI is also a physician-led organization whose mission is to improve healthcare in Canada and save lives.

Healwell AI has yet to report income, although the long-growth runway and nearly $1 billion in M&A opportunities in the clinical and digital space are clear paths to profitability. “We’re incredibly optimistic about our future trajectory, driven by a combination of organic growth and strategic mergers and acquisitions,” said its CEO, Dr. Alexander Dobranowski.

In Q1 2024 (three months ended March 31, 2024), revenue climbed 132% year-over-year to $4.58 million, while net loss improved to $6.3 million compared to $7.44 million in Q1 2023. Dr. Dobranowski believes the strategic alliance with WELL Health Technologies, Canada’s largest outpatient medical clinic owner-operator, is a competitive advantage.

This month alone, Healwell AI entered into agreements to acquire VeroSource Solutions and BioPharma Services. The former will help enterprises adopt AI-powered population health capabilities, while the latter should expand in AI-enable clinical research offerings.

On June 26, 2024, Healwell AI invested US$2 million in xAI, one of the most valuable AI companies globally. The strategic investment is a significant opportunity as it should enhance and accelerate the development of the company’s healthcare-focused data science capabilities.

Dividend investing

Rogers Sugar isn’t a flashy or high-flying stock but a reliable passive income provider. At $5.77 per share, this consumer-defensive stock pays a generous 6.2% dividend. Your $1,000 investment will generate $15.60 every quarter ($62.40 annually).

The $738 million company operates cane sugar refineries and produces sugar and maple products. In the first half of 2024, total revenues and net earnings increased 10.3% and 8% respectively to $589.6 million and $27.8 million versus the same period in 2023. Mike Walton, President and CEO of Rogers and Lantic, said the profitable growth from the business segments reflect strong product demand and improved operations.

Walton expects strong financial results in 2024 due to the ongoing capacity expansion. Rogers Sugar should continue to grow and be an enduring business. 

Profitable options

Healwell AI and Rogers Sugar are profitable investment options for beginners and thrifty investors. With a $1,000 investment, you can be a growth investor, dividend investor, or both.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Dividend Stocks

hand stacks coins
Dividend Stocks

3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These three high-yield dividend stocks still have some work to do, but each are in steady areas that are only…

Read more »

senior man and woman stretch their legs on yoga mats outside
Dividend Stocks

TFSA: 2 Canadian Stocks to Buy and Hold Forever

Here are 2 TFSA-worthy Canadian stocks. Which one is a good buy for your TFSA today?

Read more »

calculate and analyze stock
Dividend Stocks

This 5.5% Dividend Stock Pays Cash Every Single Month!

This REIT may offer monthly dividends, but don't forget about the potential returns in the growth industry its involved with.

Read more »

Silver coins fall into a piggy bank.
Dividend Stocks

How to Use Your TFSA to Earn up to $6,000 Per Year in Tax-Free Passive Income

A high return doesn't mean you have to make a high investment -- or a risky one -- especially with…

Read more »

path road success business
Dividend Stocks

2 High-Yield Dividend Stocks to Buy Hand Over Fist and 1 to Avoid

High yields are great and all, but only if returns come with them. And while two of these might, another…

Read more »

Man holds Canadian dollars in differing amounts
Dividend Stocks

This 7% Dividend Stock Pays Cash Every Month

A high dividend yield isn't everything. But when it pays out each month and offers this stability, it's worth considering!

Read more »

young people stare at smartphones
Dividend Stocks

GST/HST “Vacation”: Everything Canadians Need to Know

The GST/HST "vacation" is a little treat for the holidays, along with a $250 payment. What should you do with…

Read more »

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Is CNR Stock a Buy, Sell, or Hold for 2025?

Can CNR stock continue its long-term outperformance into 2025 and beyond? Let's explore whether now is a good time to…

Read more »